Table 3 Clinical trials aiming to cancer treatment using MSCs
From: Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Cancer type | Trial NCT number | Treatment approach | Phase | Country | Status | Year |
|---|---|---|---|---|---|---|
Hematological malignancies | NCT01045382 | MSC | II | Belgium | Recruiting | 2010 |
Hematological malignancies | NCT01092026 | Umbilical cord blood hematopoietic stem cell (UCB-HSC) transplantation with co-infusion of MSCs | I, II | Belgium | Unknown | 2010 |
Myelodysplastic syndromes | NCT01129739 | MSCs derived from human umbilical cord/placenta | II | China | Unknown | 2010 |
Solid tumors metastases | NCT01844661 | Bone marrow-derived autologous MSCs infected with ICOVIR5 (Celyvir) | I, II | Spain | Completed | 2013 |
Prostate cancer | NCT01983709 | Bone marrow-derived MSCs | I | US | Terminated (Study was Terminated by PI due to low accrual) | 2013 |
Hematological malignancies | NCT02270307 | Cyclophosphamide and MSC | II, III | Russia | Unknown | 2014 |
Ovarian cancer | NCT02068794 | Tissue-derived MSCs infected with oncolytic measles virus encoding thyroidal sodium iodide symporter (AdMSC-MV-NIS) | I, II | US | Recruiting | 2014 |
Hematological malignancies | NCT02181478 | Intra-osseous umbilical cord blood hematopoietic stem cells (UC-HSC) and MSC | I | US | Completed | 2015 |
Ovarian cancer | NCT02530047 | Bone marrow-derived MSCs expressing INF-β (BM-MSC-β) | I | US | Completed | 2016 |
Myelodysplastic syndromes | NCT03184935 | Human umbilical cord-derived MSCs | I, II | China | Suspended | 2017 |
Lung adenocarcinoma | NCT03298763 | MSCs genetically engineered to express TRAIL (MSC-TRAIL) | I, II | UK | Recruiting | 2019 |
Pancreatic cancer | NCT03608631 | MSC-derived exosomes loaded with KrasG12D siRNA | I | US | Not yet recruiting | 2019 |
Glioma | NCT03896568 | Allogeneic bone marrow-derived MSCs loaded with the oncolytic adenovirus DNX-2401 (BM-MSCs-DNX2401 | I | US | Recruiting | 2019 |